Search the Newsreel

Aroa Biosurgery Ltd (ASX: ARX) Share Price Update: Stock Declines Slightly as Health Care Index Ends Lower

Arxis jumps to within 1.7% of its high, but confirmation still trails the price move

ARXS delivered the strongest weekly return in US Industrials and sits near the top of its 52-week range, yet the inactive Trend Signal, zero activity pressure and only modest volume leave the setup balanced rather than fully confirmed.

InflaRx NV reports results for the quarter ended June 30 - Earnings Summary

InflaRx NV has reported its earnings for the quarter that ended on June 30. This summary provides key financial information from the company's performance during that period. The full article containing detailed results is available for subscribers.

InflaRx (Nasdaq: IFRX) raises $140m, funds C5a pipeline into 2029

InflaRx N.V. (Nasdaq: IFRX) recently raised $140 million through an underwritten offering, boosting its total funds to €158.4 million and extending its cash runway into 2029. The company reported a narrowed H1 net loss of €16.2 million and is focusing its pipeline on izicopan …

FMR LLC and Abigail Johnson (IFRX) disclose 5.5% Inflarx stake in Schedule 13G

FMR LLC and Abigail P. Johnson have reported a 5.5% beneficial ownership stake in Inflarx N.V. (IFRX) through a Schedule 13G filing. This amounts to 8,163,341 shares, with FMR LLC holding sole voting and dispositive power over all shares, while Abigail P. Johnson has …

Accelerant Holdings (ARX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

InflaRx N.V. (IFRX) sets up $250M shelf for stock, debt and warrants

InflaRx N.V. (IFRX) has filed a Form F-3 shelf registration to offer up to $250 million in mixed securities, including ordinary shares, debt securities, and warrants, to be issued periodically. The biopharmaceutical company, which focuses on anti-C5a/C5aR inflammatory therapies, stated that the proceeds from …

IFRX: Advanced pipeline in AAV and renal diseases, with strong funding and reduced net loss

InflaRx N.V. (IFRX) is making significant progress with its advanced pipeline in AAV and renal diseases, supported by strong financial reserves and a successful public offering. The company has reduced its expenses and net loss year-over-year and projects a cash runway extending through 2029, …

InflaRx Reports Q2 2026 Results and Business Update, Advances Izicopan in AAV and Renal Diseases

InflaRx N.V. reported its Q2 2026 financial results and provided a business update, highlighting significant progress in developing izicopan, an oral C5a receptor inhibitor, for ANCA-associated vasculitis (AAV) and other renal diseases. The company announced €158.4 million in cash and equivalents, projected to fund …

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as plannedInitiated feasibility assessment for broadened strategy for AAV in Europe Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aRPharmacokinetic …

InflaRx (IFRX) Earnings Date and Reports 2026 $IFRX

Arxis, Inc. Class A Common Stock (ARXS) extends 12-week climb to 54.7%

The move puts the aerospace and defense stock in a stronger weekly setup, though confirmation remains uneven across trend and Market Dynamics measures.

Accelerant Holdings CEO Jeffrey L. Radke disposes of 80,000 common shares worth $964,528.00

Jeffrey L. Radke, co-founder and CEO of Accelerant Holdings, sold 80,000 Class A common shares on August 3rd at an average price of $12.06 per share, totaling $964,528.00. Following this transaction, an LLC's indirect stake in the company decreased to 27,671,939 shares. This information …

InflaRx N.V. Revenue Breakdown – NASDAQ:IFRX

InflaRx N.V. (NASDAQ:IFRX) generated 0.00 USD in total revenue last year. Its top-performing segment was Novel Therapeutic Products, contributing 33.10K USD, down from 179.33K USD the previous year. The United States was the largest geographical contributor, matching the performance of the top segment.

ECARX Holdings Inc. Class A Ordinary shares (NASDAQ: ECX) Stock Price, News & Analysis

This article provides an analysis of ECARX Holdings Inc. (NASDAQ: ECX), including its stock price, fundamental financial data, and recent news. As of July 31, 2026, ECX was trading at $1.06, down 2.75%. The company, based in London, UK, specializes in automotive computing platforms …

Accelerant Holdings Class A (ARX) Stock Price | Live Quotes & Charts | NYSE

This page provides live quotes and charts for Accelerant Holdings Class A (ARX) stock, currently priced at $11.91 with a 6.34% increase. It indicates no current analyst ratings or earnings information. The content also features trading guides, stock resources, and disclaimers about the risks …

InflaRx to Report Second Quarter 2026 Results on August 6, 2026

InflaRx N.V. (Nasdaq: IFRX) announced that it will report its second-quarter 2026 financial and operating results on August 6, 2026, before the market opens. The company pioneers anti-inflammatory therapeutics and will not be hosting a conference call.

No Conference Call Planned for InflaRx's Aug. 6 Results

InflaRx (Nasdaq: IFRX) is scheduled to report its second-quarter 2026 financial and operating results on August 6, 2026, before the U.S. market opens. The biopharmaceutical company has announced that it does not plan to hold a conference call in conjunction with this release. InflaRx …

Arxis (NASDAQ: ARXS) lifts Q2 revenue 25% and repays $946M of term debt

Form 4 Accelerant Holdings For: 29 July By Investing.com

This article is a Form 4 filing from Accelerant Holdings for July 29. It includes stock market data for various indices, commodities, and bonds, along with a list of trending stocks and popular articles. The content primarily serves as a financial market update and …

ARXIS ($ARXS) Releases Q2 2026 Earnings

SpaceX Stock In Perspective: How Does It Compare To Other 2026 IPOs?

SpaceX stock is down over 50% from a short-lived peak just a few days after it went public. Here's what investors can expect for its future. Continue Reading

InflaRx NV (IFRX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of InflaRx NV (IFRX), noting its current valuation score of 6.64. The company ranks 296 out of 385 in the Biotechnology & Medical Research industry. It also highlights InflaRx NV's P/E ratio, while noting that relevant P/B, P/S, …

Arxis (ARXS) Earnings Date and Reports 2026 $ARXS

Ecarx Holdings Inc. Today's Market Trends | ECX Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey

This article provides a comprehensive overview of Ecarx Holdings Inc. (ECX), including real-time quotes, market trends, and analyst ratings. It highlights the company's healthy fundamentals and good growth potential, despite a recent weak stock market performance. The report also details key figures, institutional ownership, …

Accelerant Holdings Revenue Breakdown – NYSE:ARX

Arxis, Inc. Revenue Breakdown – NASDAQ:ARXS

InflaRx N.V. Revenue Breakdown – SWB:IF0

InflaRx N.V. reported total revenue of 0.00 EUR last year, with its top-performing segment, Novel Therapeutic Products, contributing 28.18K EUR. The United States was the primary regional contributor, accounting for 28.18K EUR of the company's revenue. This marks a significant decrease from the previous …

TradingKey

This page on TradingKey provides a detailed quarterly and annual income statement for InflaRx NV (IFRX), including a breakdown of revenues, expenses, and net income over numerous fiscal periods. It also features frequently asked questions to help users understand how to interpret the financial …

InflaRx N.V. Revenue Breakdown – BOATS:IFRX

InflaRx N.V. (IFRX) generated no revenue last year, with its top-performing segment, Novel Therapeutic Products, contributing $33.10K, down from $179.33K the previous year. The United States was the primary regional contributor to this revenue. The company's financials are detailed on TradingView, showing a significant …

IFRX|InflaRx NV|Price:1.740|Chg%:+0.010

InflaRx NV (IFRX) closed at $1.740, up 0.58%, with a high institutional ownership. The company, focused on developing monoclonal antibodies for inflammatory diseases, is in a growing phase with strong fundamentals despite recent stock market performance. Analysts rate IFRX a "Buy" with a target …

InflaRx NV (IFRX) Institutional Confidence

This article from TradingKey provides an overview of institutional confidence in InflaRx NV (IFRX). It details the shareholdings and activity of several institutional investors, including significant changes in holdings. The data was updated on July 24, 2026, showing a consistent institutional confidence score.

InflaRx NV (IFRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of InflaRx NV (IFRX), detailing its current stock price, market cap, and price momentum score. It evaluates the stock using various technical indicators like MACD, RSI, and moving averages, providing signals for buying, selling, or neutrality. The analysis …

TrivarX (ASX:TRI) Secures Critical Supply for Its Stabl-IM Imaging Clinical Trial

Accelerant Holdings CEO Jeffrey L. Radke disposes of Class A shares worth $1.29 million

Jeffrey L. Radke, co-founder and CEO of Accelerant Holdings, sold 94,777 Class A common shares between July 17-20, amounting to $1.29 million. The shares were sold at weighted average prices of $14.3 and $13.51. Following these transactions, Radke's indirect stake through an LLC decreased …

ECARX Holdings (NASDAQ: ECX) sets terms on $130M convertibles

ECARX Holdings Inc. (NASDAQ: ECX) has amended the terms of its senior unsecured convertible notes, setting the aggregate purchase price at US$130 million with capacity for an additional US$95 million. These notes bear simple interest of 5% per annum, mature on November 14, 2028, …